GlaxoSmithKline News and Research

RSS

Alli hits the stores

The first non-prescription diet drug ever to be approved by the FDA hit the shops this week and optimistic dieters are dashing out to buy it.

19 Jun 2007

OTC diet pill Alli now on sale in the U.S.

The first and only over-the-counter (OTC) product for weight loss approved by the Food and Drug Administration (FDA) has gone on sale in the U.S.

18 Jun 2007

Drug giant donates bird flu vaccine to WHO stockpile

Europe's largest drugmaker GlaxoSmithKline (GSK) has promised to donate 50 million doses of its "pre-pandemic" bird flu vaccine for humans to a global stockpile for distribution in the world's poorest countries.

14 Jun 2007

Priority review granted for oral formulation of HYCAMTIN (topotecan)

GlaxoSmithKline (GSK) has announced that its new drug application (NDA) for ORAL HYCAMTIN (topotecan) capsules, a treatment for relapsed small cell lung cancer (SCLC), has been granted Priority Review by the United States Food and Drug Administration (FDA).

14 Jun 2007

Alli weight loss drug on the U.S. market soon

Alli which is produced by GlaxoSmithKline will be available to consumers in America next week following a 150 million dollar advertising campaign to promote the non-prescription drug.

12 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007

Drug lapatinib shows activity against brain metastases

The drug lapatinib shrank tumors and slowed progression of brain metastases in some patients with advanced breast cancer, according to results of a clinical trial presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Clinical Oncology.

5 Jun 2007

More considered approach to the safety of rosiglitazone needed

A calmer and more considered approach to the safety of rosiglitazone (Avandia) - the GlaxoSmithKline treatment for type 2 diabetes - is needed to avoid unnecessary panic among patients, says an Editorial published online and in an upcoming edition of The Lancet.

28 May 2007

Tracing the path of depression

David Nutt, Professor of Psychopharmacology, said: "The development of one of these radioactive tracers to enable the study of noradrenaline and its related processes in those suffering depression is critical to our proper understanding of this disease.

27 May 2007

GSK strongly disagrees with conclusions reached in NEJM article on Avandia

GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.

22 May 2007

FDA in trouble over widely used diabetic drug Avandia

A diabetes pill which has been widely used since 1999 is now suspected of increasing the risk of heart attacks for those taking it.

22 May 2007

Sally speaks on osteoporosis story on Capitol Hill

The Society for Women's Health Research and the National Osteoporosis Foundation held a briefing on Capitol Hill to inform lawmakers about recent advances in the prevention and treatment of osteoporosis.

18 May 2007

Doctors say too many Brits addicted to OTC drugs

Doctors in Britain are warning about the dangers of becoming addicted to over-the-counter (OTC) medicines; they say more research is needed on how many misuse OTC drugs.

7 May 2007

VivoMetrics receives US patent for cough identification system

VivoMetrics has announced that the United States Patent Office has granted the company a new patent for its cough identification system algorithm.

1 May 2007

More effective therapies for individual cancers - personalized medicine

Genetic and epigenetic variations ensure that no two people are exactly alike, and the same holds true for any two cancers.

18 Apr 2007

Taking a jab at cancer by stimulating the immune system

As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress.

18 Apr 2007

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007

Coley Pharmaceutical licenses VaxImmune to Merck

Coley Pharmaceutical Group has announced that Merck & Co has licensed Coley's VaxImmune vaccine adjuvant for incorporation into vaccines being developed by Merck for certain infectious diseases and Alzheimer's disease.

15 Apr 2007

FDA approves GlaxoSmithKline's antibacterial Altabax

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved its antibacterial Altabax for the topical treatment of impetigo due to susceptible strains of Staphylococcus aureus or Streptococcus pyogenes, the two most common types of bacteria in this kind of infection.

14 Apr 2007

FDA approves Altabax ointment for impetigo

The Food and Drug Administration (FDA) approved Altabax (retapamulin ointment) for topical treatment of impetigo, a skin infection caused by bacteria.

14 Apr 2007